Arvinas Inc. (ARVN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish
Arvinas receives a Buy rating upgrade, underpinned by Veppanu's FDA approval and a robust PROTAC platform. Despite Veppanu's approval for ESR1-mutated breast cancer, ARVN's share price remains near cash value, reflecting market skepticism about future revenues. ARVN's pipeline includes five early-stage programs and a Novartis-partnered asset, but high R&D costs and uncertain milestones temper near-term upside.
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript
Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript
Arvinas Q2 Earnings Call Highlights
Arvinas NASDAQ: ARVN said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the first approved PROTAC degrader, and an out-licensing agreement for the product with Rigel Pharmaceuticals.
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Arvinas, Inc. (ARVN) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to a loss of $0.84 per share a year ago.
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
Arvinas NASDAQ: ARVN management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that may require broader development resources.
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
Arvinas Q1 Earnings Call Highlights
Arvinas NASDAQ: ARVN said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation.
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to earnings of $1.14 per share a year ago.
Arvinas (ARVN) Expected to Announce Earnings on Thursday
Arvinas (NASDAQ: ARVN - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Thursday, April 30th. Analysts expect Arvinas to post earnings of ($0.94) per share and revenue of $17.1640 million for the quarter. Individuals may visit the the company's upcoming Q1 2026 earning results page for the latest
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
Arvinas (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
